within Pharmacolibrary.Drugs.ATC.M;

model M03AC11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.04733333333333333,
    adminDuration  = 600,
    adminMass      = 0.00015,
    adminCount     = 1,
    Vd             = 0.000145,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Cisatracurium is a non-depolarizing neuromuscular blocking agent used for skeletal muscle relaxation during surgical procedures and mechanical ventilation in intensive care units. It is a benzylisoquinolinium compound and is approved for clinical use today, particularly favored due to organ-independent metabolism (Hofmann elimination), making it suitable for patients with hepatic or renal impairment.</p><h4>Pharmacokinetics</h4><p>Typical pharmacokinetics in healthy adult patients after single intravenous bolus dose; parameters largely independent of age and sex due to predominant Hoffman elimination.</p><h4>References</h4><ol><li><p>Kisor, DF, &amp; Schmith, VD (1999). Clinical pharmacokinetics of cisatracurium besilate. <i>Clinical pharmacokinetics</i> 36(1) 27–40. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199936010-00003&quot;>10.2165/00003088-199936010-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9989341/&quot;>https://pubmed.ncbi.nlm.nih.gov/9989341</a></p></li><li><p>Huang, X, et al., &amp; Wang, S (2020). Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction. <i>BMC anesthesiology</i> 20(1) 21–None. DOI:<a href=&quot;https://doi.org/10.1186/s12871-020-0935-z&quot;>10.1186/s12871-020-0935-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31969113/&quot;>https://pubmed.ncbi.nlm.nih.gov/31969113</a></p></li><li><p>Wu, Z, et al., &amp; Wu, B (2016). Altered Cisatracurium Pharmacokinetics and Pharmacodynamics in Patients with Congenital Heart Defects. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 44(1) 75–82. DOI:<a href=&quot;https://doi.org/10.1124/dmd.115.067405&quot;>10.1124/dmd.115.067405</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26470914/&quot;>https://pubmed.ncbi.nlm.nih.gov/26470914</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M03AC11;
